Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

959 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of timing, location and definition of reinfarction on mortality in patients with totally occluded infarct related arteries late after myocardial infarction.
Adlbrecht C, Huber K, Reynolds HR, Carvalho AC, Džavík V, Steg PG, Liu L, Marino P, Pearte CA, Rankin JM, White HD, Lamas GA, Hochman JS. Adlbrecht C, et al. Among authors: white hd. Int J Cardiol. 2014 Jun 1;174(1):90-5. doi: 10.1016/j.ijcard.2014.03.149. Epub 2014 Mar 28. Int J Cardiol. 2014. PMID: 24726166 Free PMC article. Clinical Trial.
The clinical profile of patients with suspected cardiogenic shock due to predominant left ventricular failure: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries in cardiogenic shocK?
Menon V, White H, LeJemtel T, Webb JG, Sleeper LA, Hochman JS. Menon V, et al. J Am Coll Cardiol. 2000 Sep;36(3 Suppl A):1071-6. doi: 10.1016/s0735-1097(00)00874-3. J Am Coll Cardiol. 2000. PMID: 10985707 Free article. Clinical Trial.
Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial.
Lincoff AM, Califf RM, Van de Werf F, Willerson JT, White HD, Armstrong PW, Guetta V, Gibler WB, Hochman JS, Bode C, Vahanian A, Steg PG, Ardissino D, Savonitto S, Bar F, Sadowski Z, Betriu A, Booth JE, Wolski K, Waller M, Topol EJ; Global Use of Strategies To Open Coronary Arteries Investigators (GUSTO). Lincoff AM, et al. Among authors: white hd. JAMA. 2002 Nov 6;288(17):2130-5. doi: 10.1001/jama.288.17.2130. JAMA. 2002. PMID: 12413372 Clinical Trial.
Echocardiographic predictors of survival and response to early revascularization in cardiogenic shock.
Picard MH, Davidoff R, Sleeper LA, Mendes LA, Thompson CR, Dzavik V, Steingart R, Gin K, White HD, Hochman JS; SHOCK Trial. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK. Picard MH, et al. Among authors: white hd. Circulation. 2003 Jan 21;107(2):279-84. doi: 10.1161/01.cir.0000045667.11911.f6. Circulation. 2003. PMID: 12538428 Clinical Trial.
The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial.
Cohen M, Gensini GF, Maritz F, Gurfinkel EP, Huber K, Timerman A, Krzeminska-Pakula M, Danchin N, White HD, Santopinto J, Bigonzi F, Hecquet C, Vittori L; TETAMI Investigators. Cohen M, et al. Among authors: white hd. J Am Coll Cardiol. 2003 Oct 15;42(8):1348-56. doi: 10.1016/s0735-1097(03)01040-4. J Am Coll Cardiol. 2003. PMID: 14563573 Free article. Clinical Trial.
Percutaneous coronary intervention for cardiogenic shock in the SHOCK trial.
Webb JG, Lowe AM, Sanborn TA, White HD, Sleeper LA, Carere RG, Buller CE, Wong SC, Boland J, Dzavik V, Porway M, Pate G, Bergman G, Hochman JS; SHOCK Investigators. Webb JG, et al. Among authors: white hd. J Am Coll Cardiol. 2003 Oct 15;42(8):1380-6. doi: 10.1016/s0735-1097(03)01050-7. J Am Coll Cardiol. 2003. PMID: 14563578 Free article. Clinical Trial.
959 results